SCHEMBL25435686

SCHEMBL25435686

Nc1ncc(-c2cc[nH]c2)c(N)n1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ DHFR P00374 6/20 0.50
▸ FGFR1 P11362 4/20 0.39
▸ SRC P12931 1/20 0.36
▸ ADORA2A P29274 2/20 0.35
▸ ADORA1 P30542 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ MAPKAPK2 P49137 1/20 0.35
▸ IKBKE Q14164 1/20 0.35
▸ TBK1 Q9UHD2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1317365 0.73 DHFR (0.66) DHFRFGFR1SRCADORA2AADORA1
SCHEMBL31612551 0.73 DHFR (0.61) DHFRADORA2AADORA1KMT2A
SCHEMBL29116207 0.73 DHFR (0.61) DHFRADORA2AADORA1KMT2A
SCHEMBL30453734 0.73 DHFR (0.66) DHFRFGFR1SRCADORA2AADORA1
SCHEMBL30725521 0.73 DHFR (0.47) DHFRFGFR1KMT2A
Hydrochloric Acid SCHEMBL12813248 0.72 DHFR (0.64) DHFRFGFR1SRCADORA2AADORA1
Hydrochloric Acid SCHEMBL1091696 0.72 DHFR (0.64) DHFRFGFR1SRCADORA2AADORA1
SCHEMBL4629601 0.70 ADORA1 (0.63) DHFRADORA2AADORA1KMT2A
SCHEMBL736022 0.70 DHFR (0.58) DHFRFGFR1SRCADORA2AADORA1
SCHEMBL1388506 0.70 DHFR (0.67) DHFRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023159307-A9 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2024-03-21 — — WO disclosed
WO-2023159307-A1 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2023-08-31 — — WO disclosed
Send feedback